PMID- 30793428 OWN - NLM STAT- MEDLINE DCOM- 20200709 LR - 20200709 IS - 1468-1331 (Electronic) IS - 1351-5101 (Print) IS - 1351-5101 (Linking) VI - 26 IP - 6 DP - 2019 Jun TI - The minimum clinically important difference: which direction to take. PG - 850-855 LID - 10.1111/ene.13941 [doi] AB - Over the past decades in modern medicine, there has been a shift from statistical significance to clinical relevance when it comes to interpreting results from clinical trials. A concept that is increasingly being used as a surrogate for clinical relevance and effect size calculation is the minimum clinically important difference (MCID). In this paper, an overview is presented of the most important aspects of the MCID concept used in research trials and a discussion of what this means for the neurological patient in clinical trials and daily practice is given. Is the MCID the best outcome measure cut-off to be implemented? CI - (c) 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. FAU - Draak, T H P AU - Draak THP AUID- ORCID: 0000-0002-3810-9007 AD - Department of Neurology, Maastricht University Medical Centre+, Maastricht, The Netherlands. FAU - de Greef, B T A AU - de Greef BTA AUID- ORCID: 0000-0003-1698-1301 AD - Department of Neurology, Maastricht University Medical Centre+, Maastricht, The Netherlands. AD - Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+, Maastricht, The Netherlands. FAU - Faber, C G AU - Faber CG AUID- ORCID: 0000-0002-2467-067X AD - Department of Neurology, Maastricht University Medical Centre+, Maastricht, The Netherlands. FAU - Merkies, I S J AU - Merkies ISJ AD - Department of Neurology, Maastricht University Medical Centre+, Maastricht, The Netherlands. AD - Department of Neurology, St Elisabeth Hospital, Willemstad, Curacao. CN - PeriNomS study group LA - eng PT - Journal Article PT - Review DEP - 20190325 PL - England TA - Eur J Neurol JT - European journal of neurology JID - 9506311 SB - IM MH - Humans MH - *Minimal Clinically Important Difference MH - *Neurology MH - Treatment Outcome PMC - PMC6593833 OTO - NOTNLM OT - minimum clinically important difference (MCID) COIS- Thomas H.P. Draak reports no disclosures. Bianca T.A. de Greef reports a grant from Prinses Beatrix Spierfonds (W.OR12-01), outside the submitted work. Catharina G. Faber reports grants from European Union's Horizon 2020 research and innovation programme Marie Sklodowska-Curie grant for PAIN-Net, Molecule-to-man pain network (grant no. 721841), grants from Prinses Beatrix Spierfonds (W.OR15-25), grants from Grifols and Lamepro for a trial on IVIg in small fibre neuropathy, and other from steering committees/advisory board for studies in small fibre neuropathy of Biogen/Convergence, Vertex and Chromocell, outside the submitted work. Ingemar S.J. Merkies received funding for research from the Talecris Talents programme, CIDP/GBS Foundation International, Prinses Beatrix Spierfonds and the European Union 7th Framework Programme (grant number 602273). Furthermore, a research foundation at the University of Maastricht received honoraria on his behalf for participation in steering committees of the Talecris ICE Study, Laboratoire francais du Fractionnement et des Biotechnologies, CSL Behring, Novartis, Grifols and Octapharma. He serves on the editorial board of the Journal of the Peripheral Nervous System, is a member of the Inflammatory Neuropathy Consortium and is a member of the Peripheral Nerve Society. EDAT- 2019/02/23 06:00 MHDA- 2020/07/10 06:00 PMCR- 2019/06/26 CRDT- 2019/02/23 06:00 PHST- 2018/11/06 00:00 [received] PHST- 2019/02/19 00:00 [accepted] PHST- 2019/02/23 06:00 [pubmed] PHST- 2020/07/10 06:00 [medline] PHST- 2019/02/23 06:00 [entrez] PHST- 2019/06/26 00:00 [pmc-release] AID - ENE13941 [pii] AID - 10.1111/ene.13941 [doi] PST - ppublish SO - Eur J Neurol. 2019 Jun;26(6):850-855. doi: 10.1111/ene.13941. Epub 2019 Mar 25.